




MAPT-201




MAPT-202




MAPT-203




MAPT-204




MAPT-205




MAPT-206



MAPT-207



MAPT-208



MAPT-209




Figure S1: Caption next page.










Figure S1: Association of SVA_67 genotype with expression of *MAPT* isoforms using the NYGC ALS cohort. Three different genotypes (AA, PA, PP) were analysed. Wilcoxon test was used to demonstrate statistical significance indicated as asterisks. * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$, ns > 0.05 .





Figure S2: Association of SVA_67 genotype with expression of *MAPT* isoforms using the PPMI cohort. Three different genotypes (AA, PA, PP) were analysed. Wilcoxon test was used to demonstrate statistical significance indicated as asterisks. * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$, ns > 0.05 .

a



b





Figure S3: Association of SVA_67 genotype with expression of *LRRC37A* isoforms using the PPMI (a) and NYGC ALS cohort (b). Three different genotypes (AA, PA, PP) were analysed. Wilcoxon test was used to demonstrate statistical significance indicated as asterisks. * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$, ns > 0.05 .

a



b




Figure S4: Association of SVA_67 genotype with expression of *ARL17A* isoforms using the PPMI (a) and NYGC ALS cohort (b). Three different genotypes (AA, PA, PP) were analysed. Wilcoxon test was used to demonstrate statistical significance indicated as asterisks. * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$, ns > 0.05 .






Figure S5: Caption next page.

CRHR1-212



CRHR1-213



CRHR1-214




Figure S5: Association of SVA_67 genotype with expression of *CRHR1* isoforms using the NYGC ALS cohort. Three different genotypes (AA, PA, PP) were analysed. Wilcoxon test was used to demonstrate statistical significance indicated as asterisks. * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$, ns > 0.05 .






Figure S6: Association of SVA_67 genotype with expression of *CRHR1* isoforms using the PPMI cohort. Wilcoxon test was used to demonstrate statistical significance indicated as asterisks. * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$, ns > 0.05 .


PLEKHM1-201




PLEKHM1-202




PLEKHM1-203




PLEKHM1-204




PLEKHM1-205




PLEKHM1-206



PLEKHM1-207



PLEKHM1-208



PLEKHM1-209




Figure S7: *Caption next page.*




Figure S7: Association of SVA_67 genotype with expression of *PLEKHM1* isoforms using the NYGC ALS cohort. Three different genotypes (AA, PA, PP) were analysed. Wilcoxon test was used to demonstrate statistical significance indicated as asterisks. * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$, ns > 0.05 .




Figure S8: Association of SVA_67 genotype with expression of *PLEKHM1* isoforms using the PPMI cohort. Three different genotypes (AA, PA, PP) were analysed. Wilcoxon test was used to demonstrate statistical significance indicated as asterisks. * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$, ns > 0.05 .






Figure S9: Capture next pages.


KANS1-212




KANS1-213




KANS1-214




KANS1-215




KANS1-216




KANS1-217




KANS1-218



KANS1-220



KANS1-221














Figure S9: Capture next page.




Figure S9: Association of SVA_67 genotype with expression of *KANSL1* isoforms using the NYGC ALS cohort. Three different genotypes (*AA*, *PA*, *PP*) were analysed. Wilcoxon test was used to demonstrate statistical significance indicated as asterisks. * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$, ns > 0.05 .




Figure S10: Association of SVA_67 genotype with expression of *KANSL1* isoforms using the PPMI cohort. Three different genotypes (AA, PA, PP) were analysed. Wilcoxon test was used to demonstrate statistical significance indicated as asterisks. * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$, ns > 0.05 .